- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04017962
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) Recipients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Genovefa Papanicolaou, MD
- Phone Number: 347-501-0044
- Email: papanicg@mskcc.org
Study Contact Backup
- Name: Yeon Joo Lee, MD
- Phone Number: 212-639-8180
- Email: leey3@mskcc.org
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Jo-Anne Young, MD
- Phone Number: 612-624-9996
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Genovefa Papanicolaou, MD
- Phone Number: 347-501-0044
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >/= 12 years (any weight)
- Have received allogenic HCT
- Have received preemptive therapy for clinically significant CMV infection post-HCT and have completed preemptive therapy no longer than 7 days prior to enrollment. Preemptive treatment includes ganciclovir, valganciclovir, foscarnet or cidofovir. Clinically significant CMV infection is defined as CMV viremia requiring preemptive therapy or CMV EOD. Patients who have received LTV prophylaxis prior to onset of clinically significant CMV infection prior to enrollment (see also exclusion criteria below).
Have one or more risk factors for recurrent CMV infection:
Human leukocyte antigen (HLA) mismatch
- HLA-related (sibling) donor with at least one mismatch at the HLA-A, -B or -DR gene loci
- Haploidentical donor
- Unrelated donor with at least one mismatch at the HLA-A, -B, -C or -DRC1gene loci, or
- Cord blood as stem cell source
- Acute or chronic GVHD requiring either topical steroids for gastrointestinal GVHD and/or systemic steroid treatment (>/= 1mg/kg/day of prednisone or equivalent dose of another corticosteroid) within 14 days prior to enrollment
- T-cell-depleted allograft ex-vivo or in-vivo T-cell depleting agents including but not limited to ATG, alemtuzimab and post HCT cyclophosphamide.
- For adult patients, able to provide written consent and complete the informed consent. For patients under 18 years, the patient's parent(s) or legal guardian(s) must provide informed consent and the patient must provide written assent to participation in the study.
- Willing and able to comply with trial instructions and requirements
- Male and female patients of childbearing potential must be willing to use a highly effective method of contraception for the course of the study. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
Subject eligibility criteria for the observational cohort:
- Age 18 years or older
- First allogenic peripheral blood or marrow HCT
- LTV prophylaxis starting <30 days post HCT and given for at least 6 weeks
Exclusion Criteria:
- Clinically significant CMV infection present at enrollment
- Breakthrough CMV infection while on primary LTV prophylaxis (unless patient non-adherent or unable to adequately absorb letermovir or documented resistance to LTV.
- Glomerular filtration rate (GFR) </= mL/min/1.73m^2(equivalent to creatinine clearance </=10 mL/min)
- Severe hepatic impairment
- Routine use of high-dose acyclovir (doses of > 800 mg twice daily), valacyclovir (doses of > 500mg twice daily), or famciclovir (doses > 500mg/day) for varicella zoster virus (VZV)/herpes simplex virus prophylaxis; limited treatment courses at higher doses for VZV infections are permissible if treatment duration dose not exceed 14 days total. Short courses of IV cidofovir for adeno virus (ADV) are permissible
- Suspected or known hypersensitivity to active or inactive ingredients of LTV formulations
- Patients treated with a medication whose administration with LTV is ontraindicated and whose discontinuation is not possible. Contraindicated medications include pimozide, ergot alkaloids and pitavastatin or simvastatin when co-administered with cyclosporine.
- Imminent demise (expected survival <6 weeks)
- Documented positive result for human immunodeficiency virus antibody (HIV-Ab) or for hepatitis C virus antibody (HCV-Ab) with detectable HCV RNA, or hepatitis B surface antigen (HBsAg) at any time prior to HCT
- Need for mechanical ventilation and/or vasopressor support at the time of enrollment
- Pregnancy or breastfeeding
- Plans to conceive or father children within the projected duration of the trial
- History of current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or would place the subject at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study.
The following antivirals are allowed up to the listed dose limits:
- Acyclovir up to 800 mg twice daily
- Valacyclovir up to 500 mg twice daily
- Famciclovir up to 500 mg/day for VZV/HSV prophylaxis; limited treatment courses at higher doses for VZV infections are permissible if treatment duration does not exceed 14 days total.
- Short courses of IV cidofovir for ADV (up to two doses)
Exclusion criteria for observational cohort:
- Clinically significant CMV infection during the 100 days following HCT. Clinically significant CMV infection defined as either CMV viremia requiring preemptive therapy with CMV antivirals or CMV end organ disease (EOD)
- Grade 3-4 GVHD
- Cord blood as cell source for HCT
- Treatment with systemic steroids (>0.5mg/kg for 2 weeks or longer) within 3 weeks prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hematopoietic cell transplantation/HCT
Participants will be hematopoietic cell transplantation (HCT) recipients with a history of CMV infection. INTERVENTIONAL COHORT: Patients receive letermovir PO QD (or IV over 1 hour for patients unable to receive PO) for 14 weeks in the absence of disease progression or unacceptable toxicity. OBSERVATIONAL COHORT: Patients undergo collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180. |
Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A).
The maximum duration of LTV administration will be 14 weeks.
Patients receiving oral medication will be administered a pill diary for drug compliance purposes.
This will be administered and reconciled in clinic.
Other Names:
Collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100.
Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The rate of breakthrough clinically significant Cytomegalovirus (CMV) infection by week 14
Time Frame: up to 24 weeks from time of study treatment
|
up to 24 weeks from time of study treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Genovefa Papanicolaou, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Disease Attributes
- DNA Virus Infections
- Herpesviridae Infections
- Infections
- Communicable Diseases
- Cytomegalovirus Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Letermovir
Other Study ID Numbers
- 19-174
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CMV
-
St George's, University of LondonSt George's University Hospitals NHS Foundation TrustCompletedCMV | Congenital Cmv | Maternal Infections Affecting Fetus or Newborn | Shedding VirusUnited Kingdom
-
Grupo Espanol de trasplantes hematopoyeticos y...Not yet recruiting
-
QIAGEN Gaithersburg, IncTerminated
-
Medical University of South CarolinaTakedaRecruitingCMV | Transplant ComplicationUnited States
-
Meridian Bioscience, Inc.Completed
-
University Hospital, LimogesUniversity Hospital, LilleCompleted
-
Imperial College LondonWithdrawnAllogeneic Stem Cell Transplantation | CMV Reactivation | Autologous CMV Specific CD8+ T CellsUnited Kingdom
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States
-
Fundación para la Investigación del Hospital Clínico...Completed
Clinical Trials on Letermovir Pill
-
The First Affiliated Hospital of Soochow UniversityRecruitingHematopoietic Stem Cell Transplantation | CMV InfectionChina
-
University Medical Centre LjubljanaRecruiting
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionUnited States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
-
National Institute of Allergy and Infectious Diseases...Merck Sharp & Dohme LLCCompletedHIV Infections | Cytomegalovirus | CMVUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCytomegalovirus InfectionFrance
-
University of PennsylvaniaMerck Sharp & Dohme LLCRecruitingCytomegalovirus Infections | Transplant-Related DisorderUnited States
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States
-
Maimónides Biomedical Research Institute of CórdobaMERCK SHARP & DOHME DE ESPAÑA S.A.Not yet recruitingInfections, CytomegalovirusSpain
-
Hospital do Rim e HipertensãoNot yet recruiting